QIAGEN N.V./$QGEN
1D1W1MYTD1Y5YMAX
Capital at risk
About QIAGEN N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
- Ticker
- $QGEN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 5,500
- Headquarters
- Venlo, Netherlands
- Website
- www.qiagen.com
QIAGEN N.V. Metrics
BasicAdvanced
$9B
22.21
$1.97
0.62
$0.35
0.80%
Price and volume
Market cap
$9B
Beta
0.62
52-week high
$57.82
52-week low
$32.53
Average daily volume
2.6M
Dividend rate
$0.35
Financial strength
Current ratio
2.849
Quick ratio
2.035
Long term debt to equity
0.485
Total debt to equity
0.49
Dividend payout ratio (TTM)
13.25%
Interest coverage (TTM)
14.01%
Profitability
EBITDA (TTM)
734.185
Gross margin (TTM)
66.38%
Net profit margin (TTM)
19.49%
Operating margin (TTM)
26.31%
Effective tax rate (TTM)
11.37%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
5.87%
Return on equity (TTM)
11.93%
Valuation
Price to earnings (TTM)
22.215
Price to revenue (TTM)
4.299
Price to book
2.69
Price to tangible book (TTM)
28.92
Price to free cash flow (TTM)
20.492
Free cash flow yield (TTM)
4.88%
Free cash flow per share (TTM)
2.132
Dividend yield (TTM)
0.80%
Forward dividend yield
0.80%
Growth
Revenue change (TTM)
2.96%
Earnings per share change (TTM)
10.36%
3-year revenue growth (CAGR)
2.02%
10-year revenue growth (CAGR)
4.95%
3-year earnings per share growth (CAGR)
6.23%
10-year earnings per share growth (CAGR)
12.56%
Bulls say / Bears say
QIAcuity is building a broader recurring consumables and assay ecosystem around its digital PCR instruments. The platform has more than 3,200 placements, over 400 customers with multiple instruments and more than 1,100 supporting publications, while new multiplex and gene-expression products are planned for later 2026. (QIAGEN)
QIAsymphony Connect expands QIAGEN’s installed-base opportunity in automated clinical extraction, including liquid biopsy, oncology and infectious-disease workflows. FDA and European listings are complete, and the launch has already generated initial customer orders on a platform with more than 3,300 historical placements. (QIAGEN)
QIAGEN is widening its molecular-diagnostics growth runway beyond respiratory and gastrointestinal testing into bloodstream infections, with a new panel covering pathogens and antimicrobial-resistance markers. Its QuantiFERON opportunity also remains sizeable: QIAGEN estimates a 75 million-test latent-TB market growing 4% to 5% annually, with only about 40% converted to blood-based testing. (Financial Times, Financial Times)
Several of QIAGEN’s newer growth initiatives are still early-stage rather than proven revenue drivers. QIAsymphony Connect has only just entered broader commercial availability and the company cites initial customer orders, so adoption and recurring consumables revenue still need to scale. (QIAGEN)
The planned QuantiFERON automation workflow and AI risk-stratification tool are not expected for initial customer use until late 2027. That leaves a long execution and regulatory timetable before these projects can materially support sales. (Financial Times)
QIAGEN’s AI drug-discovery offering is still being tested in pilots with selected pharmaceutical and biotechnology partners, with wider availability dependent on validation. This makes near-term commercial contribution uncertain and leaves execution risk around converting the technology into recurring software revenue. (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 18 Sept 2026.
Upcoming events
No upcoming events
QIAGEN N.V. News
AllArticlesVideos
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
Business Wire5 days ago
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
Business Wire4 weeks ago
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
Business Wire4 weeks ago
Funds containing QIAGEN N.V.
AllEURGBP
Fund name | Fund size | $QGEN weighting |
|---|---|---|
Amundi DAX III€DAX | €658M | 0.52% |
Amundi DAX II£DAXX | £572M | 0.45% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 0.09% |
Amundi Index MSCI Europe£CE2D | £5.1B | 0.07% |
Xtrackers MSCI Europe£XMEU | £6.7B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.